Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients
- 2 September 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 73 (12), 1655-1663
- https://doi.org/10.1007/s00228-017-2326-z
Abstract
Purpose In 2011, pioglitazone was withdrawn from the French market owing to a potential risk of bladder cancer. This study aimed at assessing the impact of this pioglitazone withdrawal (PW) considering (i) trends in antidiabetic uses and (ii) changes in hospitalization/death rates in diabetic patients following PW. Methods We first considered the general population of the Echantillon Généraliste des Bénéficiaires (EGB), a 1/97th representative sample of the French healthcare insurance system beneficiaries, for the 2010–2014 period. In this, for each non-insulinic antidiabetic drug class, changes within the numbers of monthly supplied drug units for 1000 subjects were studied through times series and Unobserved Component Models. Second, we identified from the EGB a cohort of patients who were delivered a non-insulinic antidiabetic between 01 April 2011 and 01 August 2011 (date of PW). In this, post-withdrawal incidences of all-cause hospitalization and death were compared amongst pioglitazone users and non-users using proportional subdistribution hazards models. Results PW was accompanied by an increase in metformin (+ 11.7; 95% CI 1.1–22.3) and glinide (+ 11.0; 95% CI 1.2–20.8) numbers of monthly supplied units for 1000 subjects. No significant change was found for GLP-1 agonists, DPP-4 inhibitors, sulphonylureas or alpha-glucosidase inhibitors. In the cohort of non-insulinic antidiabetic users at the time of PW (1093 pioglitazone users, 17,900 non-users), being a pioglitazone user at PW was not associated with a subsequently higher rate of hospitalization. Conclusions If PW was accompanied with significant changes in the use of some antidiabetics, no adverse impact of PW on hospitalization or death rates of diabetic type 2 patients was found.Keywords
Funding Information
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Université de Bordeaux (IdEx-HEADS)
This publication has 24 references indexed in Scilit:
- Effects of MHRA drug safety advice on time trends in prescribing volume and indices of clinical toxicity for quinineBritish Journal of Clinical Pharmacology, 2013
- Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance DatabaseDiabetologia, 2012
- Quel(s) antalgique(s) après le retrait du dextropropoxyphène ? Enquête auprès de médecins généralistes de la région Midi-PyrénéesTherapies, 2011
- Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in TaiwanClinical Therapeutics, 2009
- Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-oldsBritish Journal of Clinical Pharmacology, 2009
- Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysisBMJ, 2009
- Cardiovascular Outcomes after a Change in Prescription Policy for ClopidogrelThe New England Journal of Medicine, 2008
- Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adultsCMAJ : Canadian Medical Association Journal, 2008
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy & Therapeutics, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999